In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites ...
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, discussed the patient-site relationship, the role of technology in clinical trial delivery ...
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale. AI adoption is moving quickly in life sciences, ...
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system ...
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol ...
Why clinical development’s next AI bottleneck is not the model, but the system around it. “An AI-enabled workflow should identify the downstream implications of a change, propose aligned updates, ...
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...
Why clinical development’s next AI bottleneck is not the model, but the system around it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results